NIPH
ABBV icon

NN Investment Partners Holdings’s AbbVie ABBV Stock Holding History

NN Investment Partners Holdings’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$50.5M Buy
311,485
+12,982
+4% +$1.89M 0.27% 70
2021
Q4 		$40.4M Sell
298,503
-1,659
-0.6% -$196K 0.2% 84
2021
Q3 		$32.4M Sell
300,162
-72,115
-19% -$8.24M 0.18% 105
2021
Q2 		$41.9M Buy
372,277
+5,063
+1% +$570K 0.22% 84
2021
Q1 		$39.7M Buy
367,214
+114
+0% +$12.2K 0.23% 83
2020
Q4 		$39.3M Sell
367,100
-285,352
-44% -$27.4M 0.24% 76
2020
Q3 		$57.1M Sell
652,452
-87,850
-12% -$8.27M 0.37% 53
2020
Q2 		$72.7M Buy
740,302
+368,335
+99% +$32.4M 0.49% 41
2020
Q1 		$28.3M Sell
371,967
-121,295
-25% -$10.3M 0.23% 86
2019
Q4 		$43.7M Buy
493,262
+25,777
+6% +$2.14M 0.3% 72
2019
Q3 		$35.4M Buy
467,485
+20,882
+5% +$1.43M 0.28% 81
2019
Q2 		$32.5M Buy
446,603
+2,644
+0.6% +$208K 0.26% 91
2019
Q1 		$35.8M Sell
443,959
-227,835
-34% -$18.6M 0.28% 91
2018
Q4 		$61.9M Sell
671,794
-673,085
-50% -$59.2M 0.52% 43
2018
Q3 		$127M Buy
1,344,879
+38,466
+3% +$3.65M 0.92% 25
2018
Q2 		$121M Buy
1,306,413
+12,740
+1% +$1.24M 0.88% 24
2018
Q1 		$122M Sell
1,293,673
-150,909
-10% -$16.6M 0.88% 26
2017
Q4 		$140M Sell
1,444,582
-15,356
-1% -$1.45M 0.99% 23
2017
Q3 		$130M Buy
1,459,938
+66,697
+5% +$5.08M 0.83% 29
2017
Q2 		$101M Buy
1,393,241
+141,110
+11% +$9.49M 0.93% 26
2017
Q1 		$81.6M Buy
1,252,131
+162,556
+15% +$10.2M 0.77% 31
2016
Q4 		$68.2M Buy
1,089,575
+82,851
+8% +$5.06M 0.64% 45
2016
Q3 		$63.5M Buy
1,006,724
+146,489
+17% +$9.48M 0.6% 46
2016
Q2 		$53.3M Sell
860,235
-30,420
-3% -$1.85M 0.5% 66
2016
Q1 		$50.9M Buy
+890,655
New +$49.6M 0.49% 69

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

NN Investment Partners Holdings's ABBV Position: Q1 2022 in Review

NN Investment Partners Holdings increased its AbbVie (ABBV) stake by 4.3% in Q1 2022, buying an estimated $1.89M and bringing the position to 311,485 shares worth $50.5M. The position accounts for 0.27% of the portfolio, ranked #70.

NN Investment Partners Holdings first reported a position in ABBV in Q1 2016 and has held it in 25 quarters since. The position peaked at $140M in Q4 2017. 3,053 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

  • NN Investment Partners Holdings held 311,485 shares of AbbVie worth $50.5M as of Q1 2022.
  • NN Investment Partners Holdings bought 12,982 AbbVie shares in Q1 2022, an estimated $1.89M.
  • AbbVie made up 0.27% of NN Investment Partners Holdings's portfolio in Q1 2022, its #70 holding.
  • NN Investment Partners Holdings first reported a position in AbbVie in Q1 2016 and has held it in 25 quarters since.
  • NN Investment Partners Holdings's AbbVie position peaked at $140M in Q4 2017.
  • 3,053 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on NN Investment Partners Holdings's 13F filing for Q1 2022, filed 11 May 2022.